Effect of mesenchymal stem cells and melatonin on experimentally induced peripheral nerve injury in rats.

Autor: Khodir SA; Medical Physiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt., Imbaby S; Clinical Pharmacology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. Electronic address: samar_imbaby@med.suez.edu.eg., Abdel Allem Amer MS; Medical Physiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt., Atwa MM; Pathology Department, Faculty of Medicine, Suez University, Egypt., Ashour FA; Medical Physiology Department, Faculty of Medicine, Al-Azhar University, Egypt., Elbaz AA; Medical Physiology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Aug; Vol. 177, pp. 117015. Date of Electronic Publication: 2024 Jun 26.
DOI: 10.1016/j.biopha.2024.117015
Abstrakt: Injury of a peripheral nerve (PNI) leads to both ischemic and inflammatory alterations. Sciatic nerve injury (SNI) represents the most widely used model for PNI. Mesenchymal stem cell-based therapy (MSCs) has convenient properties on PNI by stimulating the nerve regeneration. Melatonin has cytoprotective activity. The neuroprotective characteristics of MSCs and melatonin separately or in combination remain a knowledge need. In the rats-challenged SNI, therapeutic roles of intralesional MSCs and intraperitoneal melatonin injections were evaluated by functional assessment of peripheral nerve regeneration by walking track analysis involving sciatic function index (SFI) and two electrophysiological tests, electromyography and nerve conduction velocity, as well as measurement of antioxidant markers in serum, total antioxidant capacity (TAC) and malondialdehyde, and mRNA expression of brain derived neurotrophic factor (BDNF) in nerve tissues in addition to the histopathological evaluation of nerve tissue. Both individual and combination therapy with MSCs and melatonin therapies could effectively ameliorate this SNI and promote its regeneration as evidenced by improving the SFI and two electrophysiological tests and remarkable elevation of TAC with decline in lipid peroxidation and upregulation of BDNF levels. All of these led to functional improvement of the damaged nerve tissues and good recovery of the histopathological sections of sciatic nerve tissues suggesting multifactorial synergistic approach of the concurrent usage of melatonin and MSCs in PNI. The combination regimen has the most synergistic neuro-beneficial effects in PNI that should be used as therapeutic option in patients with PNI to boost their quality of life.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: